Most monoclonal antibodies in clinical trials are owned by small biotech companies. But with blockbuster-sized revenues and approval rates higher than those for small-molecule drugs, that all may be set to change.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/nbt0905-1073 | DOI Listing |
Publication Analysis
Top Keywords
monoclonal antibody
4
antibody successes
4
successes clinic
4
clinic monoclonal
4
monoclonal antibodies
4
antibodies clinical
4
clinical trials
4
trials owned
4
owned small
4
small biotech
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!